Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Rhea-AI Summary
Palatin Technologies (NYSE American: PTN) has secured approximately $3.4 million in gross proceeds through a warrant exercise agreement with an institutional investor. The agreement involves the exercise of warrants from June 2024 and October 2023, totaling 3,907,679 shares at an amended exercise price of $0.875 per share.
As part of the inducement agreement, Palatin will issue new unregistered Series C warrants for 3,907,679 shares and Series D warrants for 1,953,839 shares, both with an exercise price of $0.875. Series C warrants are immediately exercisable with a 5-year expiration, while Series D warrants require stockholder approval. The transaction is expected to close around December 17, 2024, with proceeds intended for working capital and general corporate purposes.
Positive
- Secured $3.4 million in immediate gross proceeds through warrant exercise
- Successful restructuring of existing warrants at $0.875 per share
- Strengthened cash position for working capital needs
Negative
- Potential future dilution from new Series C and D warrants issued
- Series D warrants execution contingent on stockholder approval
- Amended warrant exercise price at $0.875 represents a pricing adjustment
News Market Reaction – PTN
On the day this news was published, PTN declined 5.03%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Pursuant to the inducement agreement, the investor has agreed to exercise a portion of its June 2024 outstanding warrants to purchase an aggregate of 2,964,283 shares of the Company's common stock and has agreed to exercise its October 2023 outstanding warrants to purchase an aggregate of 943,396 shares of the Company's common stock, both sets at an amended exercise price of
The transaction is expected to close on or about December 17, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise of warrants for working capital and general corporate purposes.
The Series C and D warrants described above are being issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and, along with the shares of common stock underlying such warrants, have not been registered under the Securities Act or applicable state securities laws.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts, including statements related to the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements reflect the Company's current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, without limitation, market and other conditions; the anticipated use of proceeds from the offering; results of clinical trials; regulatory actions by the FDA and other regulatory and the need for regulatory approvals; Palatin's ability to fund development of its technology and establish and successfully complete clinical trials; the length of time and cost required to complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin's products; and other factors discussed in Palatin's periodic filings with the SEC. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-announces-exercise-of-warrants-for-approximately-3-4-million-gross-proceeds-302332019.html
SOURCE Palatin Technologies, Inc.
FAQ
How much did Palatin (PTN) raise through the warrant exercise agreement in December 2024?
What is the exercise price for the new Series C and D warrants issued by PTN?
When do PTN's new Series C and D warrants expire?
What will Palatin (PTN) use the warrant exercise proceeds for?
